Recent safety concerns with proton pump inhibitors.

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Medicine

Background:

• Recent concerns have arisen regarding the safety of proton pump inhibitors (PPIs).
• Specific safety issues include interactions with clopidogrel, fracture risk, and hypomagnesemia.
• The Food and Drug Administration (FDA) has issued warnings concerning PPI use.

Purpose of the Study:

• To evaluate the evidence surrounding three key safety concerns associated with proton pump inhibitor (PPI) use.
• To assess the interaction between PPIs and clopidogrel.
• To examine the potential link between PPI use and fractures and hypomagnesemia.

Main Methods:

• Review of existing evidence, including in vitro studies and randomized controlled trials.
• Analysis of FDA warnings and recommendations.
• Assessment of the quality of evidence regarding PPI-related risks.

Main Results:

• An in vitro interaction between clopidogrel and some PPIs exists, though a trial showed no increased cardiovascular events with combined use.
• PPI use may be a weak risk factor for fractures, but evidence is limited and potentially confounded.
• PPI-induced hypomagnesemia is possible, with unclear mechanisms and frequency.

Conclusions:

• PPI treatment should not be withheld if genuinely indicated.
• PPIs should be used at the lowest effective dose for the shortest clinically necessary duration.
• The overall benefits of PPI therapy are considered to outweigh the identified risks.